Yamamoto, W.

sn -38 -38 cpt -11 -11 patient plasma concentration cancer sn -38g caco -2 cells irinotecan metabolite level pharmacokinetic liver glucuronidase activity study disposition sample glucuronidase activity model value infusion terminal disposition phase enzyme transport toxicity range 1998. analysis administration bilirubin 90- min i.v sampling time period 500 h apical sn -38. enterohepatic recirculation conversion serum 1999. circulation sparreboom metabolism basolateral side 14 patients cancer patients enzyme activity basolateral ratio dose level exposure phase 350 mg /m addition glucuronidation metastatic colorectal cancer compound recirculation ethyl plasma samples profile liver microsomes 5 min apical side method 1997. treatment biliary absorption human effect binding sampling rivory extent pharmacol experiment robert